摘要
目的探讨生长激素联合促性腺激素治疗男性低促性腺激素性腺功能低下而引起青春期发育迟滞的临床应用价值。方法回顾性分析2010年6月~2012年5月我院门诊就诊男性青春期发育迟滞患者28例,年龄(15.25±1.11)岁,经明确诊断后予生长激素、卵泡刺激素、人绒毛膜促性腺激素联合治疗。比较治疗前后患者性激素水平、身高、睾丸体积等发育情况变化。结果28例患者治疗后均得到随访,3个月内随访未出现近期并发症。治疗前后患者身高和睾酮水平均有显著升高(P〈0.05);睾丸体积、卯泡刺激素和黄体生成素水平有极显著升高(P〈0.01)。结论生长激素、卵泡刺激素、人绒毛膜促性腺激素联合治疗方案对男性低促性腺激素性腺功能低下引起青春期发育迟滞有一定疗效,是临床可行的安全的治疗方案。
Objective To evaluate the value and safety of combined therapy of growth hormone and gonadotropin on male de- layed puberty caused by hypogonadotropic hypogonadism. Methods A retrospective analysis was undergoing in Shanghai First Mater- nity and Infant Hospital from 2010 Jun to 2012 May. 28 cases with male delayed puberty caused by hypogonadotropic hypogonadism were enrolled. The average age was ( 15.25 ± 1.11 ) years. All the cases were given a combined therapy of human chorionic gonadotro- phin, follicle stimulating hormone and growth hormone. After 3 months therapy, the growth condition such as sexual hormone levels, height, and volume of testis were recorded to inspect the treatment effect. Results All 28 cases had a follow-up visit. No short term complications occurred. The height and testosterone level was higher than which before therapy (P 〈 0.05 ). And the volume of testis, follicle stimulating hormone and luteinizing hormone level were significantly higher than before the therapy. Conclusion Combined therapy of human chorionie gonadotrophin, follicle stimulating hormone and growth hormone could be a safe and effective method to treat male delayed puberty caused by hypogonadotropic hypogonadism.
出处
《药学实践杂志》
CAS
2013年第5期357-358,395,共3页
Journal of Pharmaceutical Practice